Abstract
Reports of post-acute COVID-19 syndrome, in which the inflammatory response persists even after SARS-CoV-2 has disappeared, are increasing1, but the underlying mechanisms of post-acute COVID-19 syndrome remain unknown. Here, we show that SARS-CoV-2-infected cells trigger senescence-like cell-cycle arrest2,3 in neighboring uninfected cells in a paracrine manner via virus-induced cytokine production. In cultured human cells or bronchial organoids, these SASR-CoV-2 infection-induced senescent cells express high levels of a series of inflammatory factors known as senescence-associated secretory phenotypes (SASPs)4 in a sustained manner, even after SARS-CoV-2 is no longer detectable. We also show that the expression of the senescence marker CDKN2A (refs. 5,6) and various SASP factor4 genes is increased in the pulmonary cells of patients with severe post-acute COVID-19 syndrome. Furthermore, we find that mice exposed to a mouse-adapted strain of SARS-CoV-2 exhibit prolonged signs of cellular senescence and SASP in the lung at 14 days after infection when the virus was undetectable, which could be substantially reduced by the administration of senolytic drugs7. The sustained infection-induced paracrine senescence described here may be involved in the long-term inflammation caused by SARS-CoV-2 infection.
Subject terms: Senescence, Virology, Ageing
This study shows that SARS-CoV-2 infection induces paracrine senescence in adjacent uninfected cells via virus-induced cytokine secretion. This resulted in a persistent inflammatory response associated with senescence even after SARS-CoV-2 disappearance.
Main
Since its emergence as a global pandemic in December of 2019, over two hundred million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)8, and a significant proportion of these people have post-acute coronavirus disease 2019 (COVID-19) syndrome, in which symptoms persist and/or sequelae occur after the virus has disappeared1. Therefore, a deeper understanding of the biological responses to SARS-CoV-2 infection, especially the persistent response, is also needed. Because COVID-19 tends to be more severe in older people, some important clues may exist in the relationship between SARS-CoV-2 infection and aging9. Although numerous changes in various biological responses are associated with aging10, the accumulation of senescent cells has recently attracted keen attention2,11. Cellular senescence is a state of irreversible cell-cycle arrest that can be induced by a variety of potentially oncogenic stimuli and thus is considered to serve as an important mechanism of tumor suppression3,12. However, unlike apoptotic cells, senescent cells do not die immediately and thereby accumulate throughout the body during the aging process2,12. Importantly, senescent cells are not merely nondividing, as they also develop a phenomenon called the SASP (ref.13) in which they secrete a variety of proinflammatory factors, such as inflammatory cytokines, chemokines, growth factors and extracellular matrix-degrading enzymes, into the extracellular fluid14–16. Thus, although the induction of cellular senescence acts primarily as a mechanism of tumour suppression, the excessive accumulation of senescent cells in vivo due to aging is thought to have adverse effects via SASP11,13. Indeed, the removal of senescent cells by genetic or pharmacological approaches reportedly delays the onset of aging-associated inflammatory diseases in aged mice7,17. These findings prompted us to examine the relationship between cellular senescence and SARS-CoV-2 infection.
Toward this purpose, we first set up a system to infect senescent cells with SARS-CoV-2 using primary normal human lung diploid fibroblasts (HDFs), which are commonly used in senescence studies12. Interestingly, the expression level of the ACE2 gene, which is required for SARS-CoV-2 to enter the cells, was increased several-fold upon the induction of cellular senescence in HDFs, as well as in other cultured primary normal human cells (Fig. 1a). This is fairly consistent with the previous observation that the levels of the ACE2 gene expression are slightly increased in lung tissues with age18. However, judging from the expression of the proteins encoded by SARS-CoV-2 and the detection of SARS-CoV-2 subgenomic RNA by Reverse transcription-quantitative polymerase chain reaction (RT-qPCR), we were unable to detect SARS-CoV-2 infection in these primary normal human cells, regardless of cellular senescence induction (Fig. 1b–d). Moreover, when ACE2 was ectopically expressed in HDFs (ACE2-HDFs) to a level comparable to that in HepG2 cells, a human cancer cell line that can be infected with SARS-CoV-2, the HDFs became infectable with SARS-CoV-2 (Fig. 1b–d and Extended Data Fig. 1a,b). Thus, although ACE2 expression tends to increase to a certain level in senescent cells, it is not high enough for SARS-CoV-2 infection, at least in these cultured primary normal human cells (Fig. 1a–d and Extended Data Fig. 1a,c). However, during this experiment, we unexpectedly noticed that signs of cellular senescence, such as cell-cycle arrest (absence of EdU incorporation)3, induction of expression of p16INK4a (ref. 6; one of the proteins encoded by the CDKN2a gene locus5) and interleukin-1β (IL-1β) (SASP factor) expression14 were observed on day 9 after SARS-CoV-2 administration (Extended Data Fig. 2a,b). This is somewhat consistent with previous reports that certain viral infections can directly induced senescence-like features in cultured cells19. Curiously, most of these senescence-like cells no longer expressed the protein encoded by SARS-CoV-2, and the SARS-CoV-2 subgenomic RNA was hardly detectable by qPCR on day 9 after SARS-CoV-2 administration to ACE2-HDFs (Fig. 1e, and Extended Data Fig. 2c), indicating that SARS-CoV-2 either decreased below the detection limit after inducing the senescence-like phenotype or indirectly prompted this phenotype in uninfected cells. To clarify this point, HDFs ectopically expressing EGFP (EGFP-HDFs), which cannot be infected with SARS-CoV-2 (Extended Data Fig. 3a), were cocultured with the HDFs ectopically expressing ACE2 (described above, ACE2-HDFs) and administered SARS-CoV-2. Intriguingly, a significant proportion of EGFP-HDFs were positive for p16INK4a (Extended Data Fig. 3b), suggesting that SARS-CoV-2 indirectly induces the senescence-like phenotype.
To determine how SARS-CoV-2 indirectly induces the senescence-like phenotype, we compared the time course of SARS-CoV-2 infection and senescence-like phenotype induction in ACE2-HDFs. Notably, SARS-CoV-2-infected cells became detectable as early as day 4 after SARS-CoV-2 administration and reached a peak on day 6, but the signs of cellular senescence appeared later, reaching a peak on day 9 when most of the SARS-CoV-2-infected cells had died (Fig. 1e, Extended Data Fig. 2c and d). These results are consistent with the observation that the expression levels of virus-induced cytokines, such as IFNβ, IL6 and TNFα, peak on day 6 after infection with SARS-CoV-2 and then decrease markedly, whereas those of other cytokines belonging to the SASP factor, such as IL1β and IL8, persist even after SARS-CoV-2 is no longer detected (Fig. 1f). Some of these virus-induced cytokines reportedly promote cellular senescence, depending on the biological context15,16. Therefore, we next tested whether SARS-CoV-2 infection causes the senescence-like phenotype indirectly through these virus-induced cytokines. The incubation of HDFs incapable of SARS-CoV-2 infection with culture supernatants of ACE2-HDFs 6 days after SARS-CoV-2 infection did indeed elicit senescence-like phenotypes, such as irreversible cell-cycle arrest and expression of p16INK4a (ref. 6; one of the genes encoded by CDKN2A gene locus5) and SASP (Fig. 2a to e). Notably, this effect was greatly attenuated in the presence of the anti-tumor necrosis factor (anti-TNF) agent, but not the anti-type I interferon (IFN) agent or anti-IL-6 agent (Fig. 2f–h). Furthermore, similar results were obtained by depleting TNF-α in SARS-CoV-2-infected cells with short interfering RNA before collecting the culture supernatant (Extended Data Fig. 4). These results suggest that TNF-α plays an important role, at least partially, in the induction of the senescence-like phenotype of HDFs by SARS-CoV-2.
Although 53BP1 foci formation, a sign of DNA damage response3, was not observed, p38 MAP kinase, a downstream signaling mediator of TNF-α20, is highly phosphorylated in SARS-CoV-2-induced senescence-like HDFs (Extended Data Fig. 5a,b). Moreover, levels of p38 phosphorylation were reduced by treatment with the anti-TNF agent, but not anti-type I-IFN agent or anti-IL-6 agent (Fig. 2i). Consistent with this observation, the induction of the senescence-like phenotype by culture supernatants from ACE2-HDFs infected with SARS-CoV-2 was partially attenuated by treatment with a p38 inhibitor (Extended Data Fig. 5c,d). These results, in conjunction with previous observations that TNF-α causes phosphorylation and activation of p38 and activated p38 induces p16INK4a expression and SASP in a DNA damage response-independent manner20–24, strongly suggest that SARS-CoV-2 provokes a senescence-like phenotype at least partly through TNF-α/p38 pathway activation. However, because these results were obtained using HDFs ectopically expressing ACE2, we sought evidence that a similar phenotype can be induced in normal human cells without ectopic ACE2 expression. To this end, we used human bronchial organoids (hBOs), which highly express endogenous ACE2 (ref. 25) (Extended Data Fig. 6a). Notably, the administration of SARS-CoV-2 to hBOs induced signs of cellular senescence after SARS-CoV-2 became undetectable, as in the case of ACE2-HDFs (Fig. 3a and Extended Data Fig. 6b–e). Furthermore, a substantial proportion of SARS-CoV-2-infected hBOs expressed activated caspase-3 (Extended Data Fig. 6f), indicating that SARS-CoV-2-infected cells are more susceptible to death, as seen in ACE2-HDFs (Extended Data Fig. 2d). This may explain why most of the senescent cells that emerge after SARS-CoV-2 becomes undetectable are SARS-CoV-2 uninfected. Furthermore, treatment with the anti-TNF agent substantially suppressed the induction of p16INK4a expression and phosphorylation of p38 in SARS-CoV-2-infected hBOs (Fig. 3b,c), ruling out the possibility that the above results simply reflect an artifact of ectopic ACE2 overexpression. Interestingly, people who have developed post-acute sequelae of SARS-CoV-2 infection reportedly have higher levels of cytokines such as TNF-α in the early stages of recovery26, consistent with our experimental data. Together, these results indicate that, at least in certain biological contexts, SARS-CoV-2 provokes paracrine senescence via cytokines secreted by infected cells. It should also be noted that the more virulent SARS-CoV-2 variant (B.1.1.7), first observed in the United Kingdom27, also induced a senescence-like phenotype in ACE2-HDFs with slightly faster kinetics than the original SARS-CoV-2 (Extended Data Fig. 7), suggesting that the induction of the senescence-like phenotype is common in normal human cells infected with SARS-CoV-2.
Considering that SASP sustains inflammatory responses4,13–16 and that the persistence of inflammation is likely to be one of the causes of post-acute COVID-19 syndrome1, we next explored the possibility that the senescence-like phenotype contributed to the sustained inflammatory response in post-acute COVID-19 syndrome. To this end, we reanalyzed data from a recently published single-cell transcriptomic analysis of lung tissue from patients with severe COVID-19 (ref. 28). In that study, SARS-CoV-2 was no longer detected in the patients with prolonged COVID-19 disease, but the pathology showed extensive evidence of damage and fibrosis resembling end-stage pulmonary fibrosis28. Notably, the expression levels of p16INK4a (CDKN2A) and several SASP factor genes, such as IL32, CXCL14 and MMP1029–31, were increased in the lung cells of patients with severe COVID-19 as compared with those of healthy individuals, especially in basal cells and, to a lesser extent, in ciliated cells (Fig. 3d and Supplementary Fig. 1). This is consistent with the observation that a significant proportion of basal cells and a slightly smaller proportion of ciliated cells express p16INK4a in SARS-CoV-2-infected hBOs after SARS-CoV-2 is no longer detectable (Fig. 3a and Extended Data Fig. 6b,d,e). Thus, it is tempting to speculate that the senescence-like phenotype induced by SARS-CoV-2 infection may be involved in the development of post-acute COVID-19 syndrome.
To further explore this possibility, we next examined whether SARS-CoV-2 infection induced p16INK4a expression in vivo using Syrian hamsters. Unlike mice, hamsters can be infected with SARS-CoV-2 (ref. 32) (Fig. 4a–c), and the expression level of p16INK4a was significantly increased from day 7 after infection in the lung, when SARS-CoV-2 became hardly detectable in hamsters (Fig. 4b–d). This is consistent with the observation that a substantial proportion of SARS-CoV-2-infected cells have positive TdT-mediated dUTP nick end labelling (TUNEL) staining, a marker of apoptosis, at day 5 after infection (Supplementary Fig. 2). Moreover, the expression levels of p16INK4a and SASP factors remained high even at days 14 and 45, when SARS-CoV-2 was almost undetectable (Fig. 4c–e), indicating that the senescence-associated inflammatory response may persist to some extent even after SARS-CoV-2 decreased below the detection limit in Syrian hamsters. Notably, this phenomenon was not observed when Syrian hamsters were infected with the influenza A (H1N1) virus, a respiratory virus that does not cause long-term symptoms after recovery1,33 (Extended Data Fig. 8), suggesting that this phenomenon is likely to be unique to SARS-CoV-2 infection. To further prove that SARS-CoV-2 provokes and sustains a senescence-associated inflammatory response, we attempted to eliminate senescent cells in Syrian hamsters by using senolytic drugs that can selectively kill senescent cells. Among the reported senolytic drugs7 we tested, ABT-263 (ref. 34) and ARV-825 (ref. 35) specifically reduced the number of senescent human fibroblasts at the reported optimal concentrations (Extended Data Fig. 9a,b). However, in hamster fibroblasts, only ABT-263 showed slight senolytic activity (Extended Data Fig. 9c,d). Moreover, the administration of ABT-263 failed to decrease the expression levels of p16INK4a and SASP factors in Syrian hamsters infected with SARS-CoV-2 (Extended Data Fig. 9e–g), suggesting that some differences may exist in the pathways that regulate the survival of senescent cells between humans and hamsters. To circumvent this problem, we used mice that are known to be sensitive to senolytic drugs7. To this end, we used a mouse-adapted strain of SARS-CoV-2 (MA10) (ref. 36), which shows dose- and age-related increases in pathogenesis in standard laboratory mice and recapitulates key features of COVID-19 in humans36. Similar to the Syrian hamsters, signs of cellular senescence, including expression of p16INK4a and p19ARF (critical inducers of cellular senescence encoded by the CDKN2A gene) and SASP factor genes, were increased at day 14 after infection in the lung, when SARS-CoV-2 became hardly detectable in BALB/c mice (Extended Data Fig. 10). Intriguingly, the administration of ABT-263 substantially decreased the expression levels of these senescence-associated genes in BALB/c mice infected with MA10 (Fig. 4f–h), further supporting the idea that SARS-CoV-2 infection provokes and sustains senescence-associated inflammatory phenotypes even after SARS-CoV-2 is no longer detectable in vivo.
During the preparation of this article, Camell et al. reported that the elimination of senescent cells, termed senolysis, reduced mortality in aged mice infected with mouse hepatitis virus (MHV), a virus in the same family as SARS-CoV-1 and 237. However, the mechanisms involved in viral entry into cells and the pathogenesis are very different between MHV and SARS-CoV-2 (ref. 38), and thus, the extent to which the data obtained from MHV can be applied to SARS-CoV-2 remains unclear. In addition, Lee et al. have recently reported that SARS-CoV-2 rapidly causes senescent phenotypes in infected cells within 5 days of infection in both cultured human cells ectopically expressing ACE2 and Syrian hamsters39. They were also able to eliminate senescent cells by administering senolytic drugs such as ABT-263 or dasatinib plus quercetin (D + Q) to SARS-CoV-2-infected hamsters using a protocol similar to ours39. The reason why we could not reproduce their data is currently unknown, but these seemingly disparate results may reflect differences in the cell types used and the environments in which the hamsters were raised. Nevertheless, both our study and that of Lee et al. showed that the administration of senolytic drugs to SARS-CoV-2-infected rodents reduced the levels of inflammatory factors classified as SASP (Fig. 4h), implying that senolysis may be effective in alleviating post-acute COVID-19 syndrome. However, SASP has both harmful and beneficial effects3,12,13, and it has recently been reported that the removal of accumulated senescent cells in mice resulted in severe liver dysfunction40. In this regard, it is interesting to note that hamsters infected with SARS-CoV-2 showed resistance to superinfection with influenza virus A H1N1 (Supplementary Fig. 3). Thus, it is also tempting to speculate that SARS-CoV-2-induced senescent cells may have some beneficial effects, depending on the biological context. Accordingly, a more rigorous analysis is needed to determine whether senolysis can serve as a preventive measure against post-acute COVID-19 syndrome. Nevertheless, our findings provide valuable new insights into the mechanism of post-acute COVID-19 development1 and suggest new possibilities for its control.
Methods
Animal experiments
All animal experiments were approved by the Animal Research Committee of the Research Institute for Microbial Diseases, Osaka University. Four-week-old male Syrian hamsters were purchased from SLC Japan. SARS-CoV-2 (5.6 × 105 p.f.u. per 80 μl) infections were performed as previously described41. At 3 days after infection, animals were randomly divided into the vehicle (5% DMSO and 4% Tween-20 in PBS) or ABT-263 (100 mg kg−1 body weight) group, and intraperitoneally treated for days 3–7 and days 10–13 after infection. On day 14 post-infection, animals were euthanasia and perfused by using 10 U ml−1 heparin (Mochida Pharmaceutical, 224122557) containing PBS. Isolated lungs were immediately soaked to RNA later (Sigma, R0901) overnight or 4% PFA for 72 h at 4°C. Ten-week-old female BALB/c mice were purchased from SLC Japan. MA10 (1.0 × 104 p.f.u. per 50 μl) intranasal infection was performed the same way as Syrian hamster. After animals awoke from anesthesia, ABT-263 dissolved in 10% EtOH, 30% polyethylene glycol 400 and 60% Phosal 50 PG were administered orally. The dose of ABT-263 was 100 mg kg−1 on days 0–3, 50 mg kg−1 on days 5–9 and 50 mg kg−1 on days 11–13. Lungs were isolated after euthanasia, soaked to TRIzol and homogenized. Lung RNA isolation was performed using TRIzol according to the manufacturer’s protocol. In Fig. 4f–h, animals that died before day 14 were excluded. In the other experiments, no animals were excluded from the analysis.
Cell culture
Normal HDFs, TIG-3 cells (Japanese Cancer Research Resources Bank (JCRB), 0506), Vero cells (ATCC, CCL-81), VeroE6/TMPRSS2 cells (JCRB, 1819), HepG2 cells (JCRB, 1054) and Syrian hamster embryo fibroblasts established from day 10 hamster embryos (kindly provided by H. Siomi, Keio University) were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (MP Biomedicals, 2917354H) and 100 U ml−1 penicillin/streptomycin (Sigma, P4333), described as normal culture medium. Normal human bronchial/tracheal epithelial cells, NHBE cells (Lonza, CC-2540) and normal human colonic epithelial cells and HCoEpiCs (ScienCell, 2950) were cultured BEBM basal medium (Lonza, CC-3171) supplemented with the BEBM SingleQuots Kit (Lonza, CC-4175) or colonic epithelial cell medium (CoEpiCM, 2951) following the manufacturer’s protocol. Madin–Darby canine kidney (MDCK) cells (kindly provided T. Watanabe, Osaka University) were maintained in minimal essential medium (Gibco) supplemented with 5% newborn calf serum (Gibco) at 37 °C with 5% CO2. MDCK cells were used for plaque assays to titrate H1N1 viruses. For establishing ACE2-HDFs and EGFP-HDFs, retroviral transduction was carried out. Cells were infected with retroviruses encoding ACE2 (in pMarX-hygro) or EGFP/ELuc (in pMarX-puro) and selected by hygromycin (50 μg ml−1) or puromycin (100 ng ml−1), respectively, for 24 h (ref. 42). Cellular senescence was induced by treatment with doxorubicin (DXR) at the following cell densities and DXR concentrations: HDFs and ACE2-HDFs, 8 × 103 cells per cm2, DXR 250 ng ml−1; NHBE cells, 3 × 103 cells per cm2, DXR 150 ng ml−1; HCoEpiCs, 8 × 103 cells per cm2, DXR 250 ng ml−1. After 9 days of treatment with DXR, cells were used as senescent cells. We regularly confirmed the absence of mycoplasma contamination in our cultured cells.
BOs and BO-derived ALI culture
Bronchial organoids (BOs) were generated as described previously25. Briefly, to generate BOs, NHBEs (Lonza, CC-2540) were suspended in 10 mg ml−1 cold Matrigel growth factor reduced basement membrane matrix and then cultured with the differentiation medium for 10 days. To generate a BO-derived air–liquid interface (ALI) model, expanding BOs were seeded into Transwell inserts (Corning) in a 24-well plate (3 × 104 cells per well) and then cultured with the differentiation medium for 5 days. The medium was only placed into the bottom chamber to maintain the ALI culture condition.
Virus preparation
SARS-CoV-2 strains SARS-CoV-2/Hu/DP/Kng/19-020 and SARS-CoV-2/Hu/DP/Kng/19-027 were provided by the Kanagawa Prefectural Institute of Public Health, and SARS-CoV-2 strain hCoV-19/Japan/QHN002/2021 was provided by the National Institute of Infectious Disease. SARS-CoV-2 was isolated from a patient with COVID-19 (GenBank: LC528233.1). All viruses were propagated in Vero cells or VeroE6/TMPRSS2 cells and titers determined by a TCID50 or plaque assay as described previously41. All experiments, including virus infections, were done in a biosafety level 3 facility at Osaka University and Kyoto University strictly following regulations. SARS-CoV-2/Hu/DP/Kng/19-020 was used in most experiments. SARS-CoV-2/Hu/DP/Kng/19-027 and GenBank: LC528233.1 were used for hBO experiments. hCoV-19/Japan/QHN002/2021 was used for experiments shown in Extended Data Fig. 7 and Syrian hamster experiments. Mouse-adapted SARS-CoV-2 (MA10), established by a reverse genetics method named CPER (circular polymerase extension reaction)43, was grown in Vero/TMPRSS2 cells, and the titer was measured using a TCID50 assay. A/California/04/2009 (H1N1; CA04), which was kindly provided by Y. Kawaoka at the University of Tokyo, was propagated at 37°C in MDCK cells to make the viral stock. Virus titers were determined by plaque assays in MDCK cells.
In vitro SARS-CoV-2 infection experiments
ACE2-HDFs, EGFP-HDFs, HDFs, HepG2, NHBE and HCoEpiCs were seeded and cultured 24 h at 37°C, 5% CO2. Before virus infection, the medium was replaced with Dulbecco’s modified Eagle’s medium supplemented with 2% fetal bovine serum following two washes in PBS. Then, cells were infected with SARS-CoV-2 (1.0 m.o.i.). At 24 h of infection, the medium was replaced with normal culture medium after two washes in PBS. BO-ALI was infected with SARS-CoV-2 (0.1 m.o.i.). The medium containing SARS-CoV-2 was plated into the top chamber. At 120 min after infection, the medium was removed from the top chamber to reestablish the ALI culture condition. The culture medium in the bottom chamber was replaced with fresh differentiation medium at 1, 2 and 3 days after infection. TNF-α inhibitor (etanercept, 500 μg ml−1) was added to SARS-CoV-2-infected hBOs at day 3 after infection.
Immunofluorescence and immunohistochemistry
Immunofluorescence and immunohistochemistry were performed by using primary antibodies against SARS-CoV-2 spike protein (GeneTex, GTX632604; 1:1,000), SARS-CoV-2 nucleocapsid protein (Sino Biological, 40143-R001; 1:1,000), p16INK4a (Santa Cruz Biotechnology, sc-56330; 1:200), IL-1β (Proteintech, 16806-1-AP; 1:200), IL-8 (Bioss Antibodies, bs-0780R; 1:50), 53BP1 (Santa Cruz Biotechnology, sc-22760; 1:1,000), phospho-p38 (Cell Signaling Technology, 4511; 1:1,000), cleaved caspase-3 (Cell Signaling Technology, 9664; 1:500), ACE2 (R&D Systems, AF933; 1:100), KRT5 (BioLegend, 905903; 1:200) and FoxJ1 (R&D Systems, AF3619; 1:80). The following secondary antibodies were used for immunofluorescence: Alexa Fluor donkey anti-mouse 488 (Invitrogen, A21202; 1:1,000), anti-mouse 555 (Invitrogen, A-31570; 1:1,000), anti-rabbit 568 (Invitrogen, A10042; 1:1,000) and anti-goat 647 (Invitrogen, A-21447; 1:1,000). For immunohistochemistry, we used goat anti-rabbit IgG (Vector Laboratories, BA-1000; 1:1,000). TUNEL staining was performed using the In Situ Cell Death Detection Kit with TMR red (Roche, 12156792910) according to the manufacturer’s protocol. Briefly, TUNEL staining was performed before normal immunofluorescence staining. Fluorescence images were observed using an all-in-one fluorescence microscope (Keyence, BZ-710) or upright microscope (Olympus, BX53). The number of positive signals in the images was calculated in an automated manner using BZ-X 700 analyzer software (Keyence, v1.4.1.1).
RNA isolation and RT-qPCR
Total RNA was extracted using TRIzol (Thermo Fisher Scientific, 15596026) or the RNeasy mini kit (Qiagen, 74104) according to the manufacturer’s protocol. cDNA was synthesized using a PrimeScript RT reagent kit (Takara Bio, PR047A). The mRNA expression levels of each gene were calculated relative to β-actin or GAPDH expression levels using quantitative qPCR. The PCR primer sequences used are described in Supplementary Table. 1.
Cell proliferation assay
Live cells were photographed using an Eclipse Ts2R inverted microscope (Nikon) for the indicated time points. Cell numbers were counted using ImageJ (Fiji), and relative cell numbers were calculated.
Senolysis assay
Normal HDFs and Syrian hamster embryo fibroblasts were rendered senescent by 250 ng ml−1 DXR for 9 days or 150 ng ml−1 DXR for 6 days, respectively. After senescence induction, senescent cells and control early-passage cells were seeded at 5 × 103 cells per cm2 and cultured for 24 h. Then, the senolytic drugs ABT-263 (Selleck, S1001; 1 μM), ARV-825 (Medchem Express, HY-16954; 25 nM), BPTES (Cayman, 19284; 10 μM), dasatinib (LC Laboratories, D-3307; 2 μM) and quercetin (Cayman, 10005169; 20 μM) were added. After 72 h of culture with senolytic drugs, live-cell numbers were counted using trypan blue staining (Invitrogen, T10282), or cells were fixed by 4% paraformaldehyde for 15 min at room temperature. These fixed cell counterstains were utilized DAPI (Dojindo, 340-07971; 1:2,000) for 1 h at room temperature. The photographs were observed using an all-in-one fluorescence microscope (Keyence, BZ-710).
Induction of cellular senescence using culture supernatants of SARS-CoV-2-infected cells
ACE2-HDFs were infected with SARS-CoV-2 at m.o.i. of 1.0. After 6 days of culture, the supernatant was collected and removed debris by a centrifuge (1,100 × g, 15 min). For the preparation of TNF-α knockdown cell supernatant, 3 days after infection, siControl (Santa Cruz Biotechnology, sc-37007) or siTNF-α (Santa Cruz Biotechnology, sc-37216) were transfected using lipofectamine RNAiMAX (Invitrogen, 13778075); at day 6 after infection, the supernatant was collected and debris removed by centrifuge (1,100 × g, 15 min). HDFs were seeded at 8.0 × 103 cells in 6-well plates and treated with the supernatant of SARS-CoV-2-infected cells and normal culture medium at a ratio of 1:1. The TNF-α inhibitor etanercept (Pfizer, 46359771; 500 μg ml−1), the IL-6R inhibitor tocilizumab (Selleck, A2012; 50 μg ml−1), type I IFN neutralization antibody (PBL Assay Science, 39000-1; 1:200) and the p38 MAP kinase inhibitor SB203580 (Selleck, S1076; 10 μM) were administrated at the indicated dose.
Single-cell RNA sequencing
Single-cell RNA-sequencing data (GSE158127) (ref. 28) were reanalyzed by focusing on CDKN2A and SASP factor gene expression in epithelial cells using Seurat v3.2.3 and doublet detection by Doublet Finder v2.0.3.
Immunoblotting
Cells were lysed by RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton-X 100 and 1% sodium deoxycholate). Protein sample were suspended 4× Laemmli sample buffer, 50 mM Tris-HCl, pH 6.8, 4% SDS, 10% glycerol, 0.1% bromophenol blue and 1 mM DTT and boiled at 95°C for 5 min in BSL-3. The determination of protein concentration and immunoblotting were performed as previously described35. The primary antibodies used were β-actin (Sigma, A5316; 1:1,000), ACE2 (R&D Systems, AF933; 1:1,000), phospho-p38 (Cell Signaling Technology, 4511; 1:1,000) and p38 (Cell Signaling Technology, 9212; 1:1,000). The membranes were then incubated with the secondary antibodies (Cell Signaling Technology, 1:10,000) and visualized with Amersham ECL Prime (GE Healthcare), followed by detection with chemiluminescence using Amersham ImageQuant 800 (Cytiva).
Statistics
All data were visualized and analyzed in Prism (v.9.1.2). Statistical significance was determined by a two-tailed unpaired Student’s t test (Figs. 1a and 2d,e; Extended Data Figs. 1b, 2a,b, 3b, 5a,b and 6a,d,e; and Supplementary Fig. 3c), two-way ANOVA followed by Sidak’s multiple comparison test (Figs. 1e,f, 3a and 4a; Extended Data Figs. 2d, 6b,c,f, 7a,b and 9b,d,e; and Supplementary Fig. 3b), one-way ANOVA followed by Dunnett’s multiple comparison test (Figs. 2h,i, 3b,c and 4c–e,g,h and Extended Data Figs. 4b,c, 5d and 10b) or one-way ANOVA followed by Tukey multiple comparison tests (Extended Data Fig. 8d). P values < 0.05 were considered significant. No statistical methods were used to predetermine sample sizes, but our sample sizes were similar to those reported in the previous publications39. Data distribution was assumed to be normal, but this was not formally tested. For all experiments, animals and/or cell culture wells were randomly assigned to experimental groups. Data collection and analysis were not performed blind to the conditions of the experiments.
Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
We thank J. Sakuragi and T. Takahashi (Kanagawa Prefectural Institute for Public Health) for providing SARS-CoV-2. We also thank A. Bharat (Northwestern University) and coworkers for making their single-cell transcriptomic data available to the public, Y. Koyanagi and K. Shimura (Kyoto University) for their help in setting up and running the BSL-3 facility at Kyoto University, H. Siomi (Keio University) for providing primary hamster fibroblasts, and M. Suzuki (Osaka University) for technical support throughout the study. We are grateful to members of Hara’s laboratory for helpful discussions during the preparation of this manuscript. This work was supported in part by the Japan Agency of Medical Research and Development (grants 21gm5010001h0005 and 20fk0108533h0001), the Japan Science and Technology Agency (grant JPMJMS2022-15), the Joint Usage/Research Center program of the Institute for Frontier Life and Medical Sciences at Kyoto University and the Mitsubishi Foundation (grant 202012016).
Extended data
Source data
Author contributions
E.H. designed the experiments, analyzed the data, oversaw the project and wrote the manuscript. S. Tsuji did most of the experiments. S.M., T.S., M.S., S. Torii, C.O., S. Shichinohe, M.Y. and Y.M. helped analyze SARS-CoV-2 infection. R.H., S. Sato and K.T. helped perform organoid experiments. Y.K. helped analyze single-cell transcriptomic data. T. Kondo, M.W., S.O., S.N., T. Matsudaira, T. Matsumoto and S.K. helped with senescence induction. T. Kobayashi and T.O. analyzed data.
Peer review
Peer review information
Nature Aging thanks Carmen Rivas and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Data availability
RNA-sequencing data that support the findings of this study have been deposited in the DNA Data Bank of Japan with the accession number PRJDB11886 (https://ddbj.nig.ac.jp/DRASearch/). All other data supporting the findings of this study are available from the corresponding author upon reasonable request.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
is available for this paper at 10.1038/s43587-022-00170-7.
Supplementary information
The online version contains supplementary material available at 10.1038/s43587-022-00170-7.
References
- 1.Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601–615. doi: 10.1038/s41591-021-01283-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.He S, Sharpless NE. Senescence in health and disease. Cell. 2017;169:1000–1011. doi: 10.1016/j.cell.2017.05.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Gorgoulis V, et al. Cellular senescence: defining a path forward. Cell. 2019;179:813–827. doi: 10.1016/j.cell.2019.10.005. [DOI] [PubMed] [Google Scholar]
- 4.Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. Mech. Dis. 2010;5:99–118. doi: 10.1146/annurev-pathol-121808-102144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
- 6.Hara E, et al. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 1996;16:859–867. doi: 10.1128/MCB.16.3.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Di Micco R, Krizhanovsky V, Baker D, d’Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 2021;22:75–95. doi: 10.1038/s41580-020-00314-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.O’Driscoll M, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590:140–145. doi: 10.1038/s41586-020-2918-0. [DOI] [PubMed] [Google Scholar]
- 10.López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194–1217. doi: 10.1016/j.cell.2013.05.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Akbar AN, Gilroy DW. Aging immunity may exacerbate COVID-19. Science. 2020;369:256–257. doi: 10.1126/science.abb0762. [DOI] [PubMed] [Google Scholar]
- 12.Chan ASL, Narita M. Short-term gain, long-term pain: the senescence life cycle and cancer. Genes Dev. 2019;33:127–143. doi: 10.1101/gad.320937.118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Rodier F, Campisi J. Four faces of cellular senescence. J. Cell Biol. 2011;192:547–556. doi: 10.1083/jcb.201009094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Coppé J-P, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:e301. doi: 10.1371/journal.pbio.0060301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Acosta JC, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133:1006–1018. doi: 10.1016/j.cell.2008.03.038. [DOI] [PubMed] [Google Scholar]
- 16.Kuilman T, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019–1031. doi: 10.1016/j.cell.2008.03.039. [DOI] [PubMed] [Google Scholar]
- 17.Baker DJ, et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature. 2016;530:184–189. doi: 10.1038/nature16932. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Chow RD, Majety M, Chen S. The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2. Nat. Commun. 2021;12:4. doi: 10.1038/s41467-020-20323-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kelley WJ, Zemans RL, Goldstein DR. Cellular senescence: friend or foe to respiratory viral infections? Eur. Respir. J. 2020;56:2002708. doi: 10.1183/13993003.02708-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Beyaert R, et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 1996;15:1914–1923. doi: 10.1002/j.1460-2075.1996.tb00542.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Iwasa H, Han J, Ishikawa F. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway: p38 activation in senescence. Genes Cells. 2003;8:131–144. doi: 10.1046/j.1365-2443.2003.00620.x. [DOI] [PubMed] [Google Scholar]
- 22.Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype: p38 regulates the senescence secretory phenotype. EMBO. 2011;30:1536–1548. doi: 10.1038/emboj.2011.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Mavrogonatou E, Konstantinou A, Kletsas D. Long-term exposure to TNF-α leads human skin fibroblasts to a p38 MAPK- and ROS-mediated premature senescence. Biogerontol. 2018;19:237–249. doi: 10.1007/s10522-018-9753-9. [DOI] [PubMed] [Google Scholar]
- 24.Del Rey MJ, et al. Senescent synovial fibroblasts accumulate prematurely in rheumatoid arthritis tissues and display an enhanced inflammatory phenotype. Immun. Ageing. 2019;16:29. doi: 10.1186/s12979-019-0169-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Suzuki, T. et al. Generation of human bronchial organoids for SARS-CoV-2 research. Preprint at bioRxiv10.1101/2020.05.25.115600 (2020).
- 26.Peluso MJ, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 2021;224:1839–1848. doi: 10.1093/infdis/jiab490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Volz E, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593:266–269. doi: 10.1038/s41586-021-03470-x. [DOI] [PubMed] [Google Scholar]
- 28.Bharat A, et al. Lung transplantation for patients with severe COVID-19. Sci. Transl. Med. 2020;12:eabe4282. doi: 10.1126/scitranslmed.abe4282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ruhland MK, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun. 2016;7:11762. doi: 10.1038/ncomms11762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Schafer MJ, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 2017;8:14532. doi: 10.1038/ncomms14532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kandhaya-Pillai R, et al. TNFα-senescence initiates a STAT-dependent positive feedback loop, leading to a sustained interferon signature, DNA damage, and cytokine secretion. Aging. 2017;9:2411–2435. doi: 10.18632/aging.101328. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Imai M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA. 2020;117:16587–16595. doi: 10.1073/pnas.2009799117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Iwatsuki-Horimoto K, et al. Syrian hamster as an animal model for the study of human influenza virus infection. J. Virol. 2018;92:e01693-17. doi: 10.1128/JVI.01693-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Chang J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 2016;22:78–83. doi: 10.1038/nm.4010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Wakita M, et al. A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells. Nat. Commun. 2020;11:1935. doi: 10.1038/s41467-020-15719-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Leist SR, et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell. 2020;183:1070–1085. doi: 10.1016/j.cell.2020.09.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Camell CD, et al. Senolytics reduce coronavirus-related mortality in old mice. Science. 2021;373:eabe4832. doi: 10.1126/science.abe4832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv. Virus Res. 2011;81:85–164. doi: 10.1016/B978-0-12-385885-6.00009-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Lee S, et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature. 2021;599:283–289. doi: 10.1038/s41586-021-03995-1. [DOI] [PubMed] [Google Scholar]
- 40.Grosse L, et al. Defined p16High senescent cell types are indispensable for mouse healthspan. Cell Metabo. 2020;32:87–99. doi: 10.1016/j.cmet.2020.05.002. [DOI] [PubMed] [Google Scholar]
- 41.Higuchi Y, et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat. Commun. 2021;12:3802. doi: 10.1038/s41467-021-24013-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Takahashi A, et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat. Cell Biol. 2006;8:1291–1297. doi: 10.1038/ncb1491. [DOI] [PubMed] [Google Scholar]
- 43.Torii S, et al. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction. Cell Rep. 2021;35:109014. doi: 10.1016/j.celrep.2021.109014. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
RNA-sequencing data that support the findings of this study have been deposited in the DNA Data Bank of Japan with the accession number PRJDB11886 (https://ddbj.nig.ac.jp/DRASearch/). All other data supporting the findings of this study are available from the corresponding author upon reasonable request.